NEWS

Celebrating 20 Years of Success with Cromos Pharma We proudly celebrate 20 years of dedication, innovation, and growth. It’s been an incredible journey, and we’re grateful for the trust and support of our clients, partners, and team members who have been part of this path. From our humble beginnings to becoming a trusted name in clinical research, we’ve achieved so much together, and

New Cromos Pharma’s Office in Portugal

Expanding Horizons: “Syngene – Cromos Pharma” Alliance Transforms Clinical Research

Successful Partnership Between MAIA Biotechnology and Cromos Pharma MAIA Biotechnology and Cromos Pharma have partnered up in an innovative collaboration to advance cancer treatment. Mutual collaborative efforts are focused on THIO, a groundbreaking telomere-targeting agent for non-small cell lung cancer (NSCLC). In a trial presented at ASCO 2024, THIO demonstrated an impressive 85% disease control rate. Read more in the press release: https://www.pr.com/press-release/914337

Cromos Pharma’s Agnieszka Milewska-Kranc Leads the Way in EU’s Rare Disease Advocacy In accordance with the Decision of the European Parliament and the Council of the EU establishing the Second Program of Action in the Field of Health, the EU Council Recommendation on Action in the Field of Rare Diseases was issued. This recommendation urges member states to establish and implement plans for rare diseases. The National

We are at the BIO International Convention 2024